{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-093321","form_type":"8-K","ticker":"RAPP","cik":"0002012593","company_name":"Rapport Therapeutics, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.354397+00:00","generated_at":"2026-05-31T11:22:11.172172+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Rapport Therapeutics Q2 net loss $18.1M; cash $336.1M; IPO raised $174.4M gross","bullets":["Net loss $18.1M vs $6.4M YoY; R&D expense $15.7M vs $4.7M YoY.","Cash, cash equivalents and short-term investments $336.1M, expected to fund operations through end of 2026.","IPO with concurrent private placement raised $174.4M gross ($157.6M net).","Phase 2a trial of RAP-219 in focal epilepsy on track for Q3 2024 initiation; topline data mid-2025.","Board member Terry-Ann Burrell to transition off board after Form 10-Q filing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-093321","json":"https://secwatch.observer/filing/0000950170-24-093321.json","markdown":"https://secwatch.observer/filing/0000950170-24-093321.md","text":"https://secwatch.observer/filing/0000950170-24-093321.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2012593/000095017024093321/0000950170-24-093321-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2012593/000095017024093321/rapp-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:22:11.172172+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}